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prostatectomy with or without the pelvic
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Background: While evidence on safety and efficacy of primary hypofractionated radiotherapy in prostate cancer is
accumulating, data on postoperative hypofractionated treatment of the prostate bed and of the pelvic lymph
nodes is still scarce. This phase II trial was initiated to investigate safety and feasibility of hypofractionated treatment
of the prostate bed alone or with the pelvic lymph nodes.
Methods/design: A total of 80 prostate cancer patients with the indication for adjuvant radiotherapy will be
enrolled, where 40 patients with a low risk of lymph node involvement (arm 1) and another 40 patients with a
high risk of lymph node involvement (arm 2) will each receive 54 Gy in 18 fractions to the prostate bed. Arm 2
will be given 45 Gy to the pelvic lymph nodes additionally. Helical Tomotherapy and daily image guidance will
be used.
Discussion: This trial was initiated to substantiate data on hypofractionated treatment of the prostate bed and
generate first data on adjuvant hypofractionated radiotherapy of the pelvic lymph nodes.
Trial registration: ClinicalTrials.gov; NCT01620710
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With 58.000 newly diagnosed cases every year in Germany,
prostate cancer is the most common cancer of men in
Germany. As the proportion of men older than 60 years is
estimated to rise with the demographic shift up to 37% in
2050, prostate cancer will gain more and more epidemio-
logical and economical significance [1]. For patients
with localised prostate cancer, radical prostatectomy and
definitive radiotherapy are primary treatment options. The
guidelines of the German Society of Urology strongly rec-
ommend postoperative radiotherapy for patients with stage
pT3 and positive margins. In addition, adjuvant radiother-
apy should be considered for stage pT3 with negative mar-
gins and pT2 with positive margins [1]. In the case of a* Correspondence: sonja.krause@med.uni-heidelberg.de
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reproduction in any medium, provided the orrecurring PSA elevation, salvage radiotherapy should be
started early [2].
Three phase III trials demonstrated a superior bio-
chemical recurrence-free survival (PSA-BFS) for adjuvant
radiotherapy compared to surgery alone: EORTC 2291
[3], SWOG 8794 [4] and ARO 96–02 [5]. Additionally,
an update of SWOG 8794 trial exhibited an advantage in
overall survival for adjuvant radiotherapy [6]. While the
toxicity profile of definitive radiotherapy is well charac-
terised, data on side effects of adjuvant irradiation is rela-
tively sparse. Patients in the EORTC trial showed more
side effects in the radiotherapy arm, however, the rate of
NCI CTC AE toxicities grade 3 or higher was comparable
to the control arm. In the ARO trial, 3% of the irradiated
patients suffered from acute, and 2% of late grade 3 blad-
der toxicities and 10% showed grade 2 late rectal toxicity.
Irradiation of the pelvic lymph nodes (whole pelvis
radiotherapy, WPRT) in patients with a high risk of lymphLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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subject to discussion. While some randomised trials could
demonstrate a benefit for the WPRT in a definitive setting
(RTOG 94–13 [7]), others could not (RTOG 77–06 [8],
GETUG-01 [9]). For postoperative WPRT, Spiotto et al.
[10] showed in a retrospective analysis of 160 high-risk
patients an improved 5-year BFS.
In recent years, hypofractionated radiotherapy, i.e. the
treatment with an increased daily dose, has gained im-
portance in prostate cancer radiotherapy. The radiation-
induced death of mammalian cells is a function of total
dose, daily dose and treatment duration. The radiation
sensitivity of normal tissues and cancer cells is described
by the α/β value using the linear-quadratic model. The
α/β value appears to be high (≥ 10 Gy) for so-called
early-reacting tissues (e.g. skin, mucosa and most tumor
cells) and low (< 5 Gy) for late-reacting tisuses (e.g.
spinal cord and bone). Differences in the α/β values
between normal tissues and tumor cells are the basis for
developing fractionation regimes in radiation oncology.
For prostate cancer cells, in vitro studies and retrospect-
ive analyses have indicated an α/β value as low as 1.5 Gy
(and thus lower than the respective values for rectum
and bladder), implying that patients with prostate cancer
might benefit from treatment with high daily doses [11].
For primary radiotherapy, several non-randomised pro-
spective trials have demonstrated comparable rates of
acute and late toxicity and, in particular, similar efficacy
when comparing hypofractionated and conventionally
fractionated radiotherapy: Kupelian et al. [12] saw in a
phase I/II trial when treating with 70 Gy in 2.5 Gy single
doses a low rate of rectal toxicity and a biochemical dis-
ease control comparable to patients treated with conven-
tional fractionation. An early analysis of an Italian phase
III trial [13] comparing 62 Gy in 3.1 Gy single doses to
80 Gy in conventional fractionation reported a 3-year
grade 2 rectal toxicity of 17% vs. 16% and grade 3 geni-
tourinary (GU) toxicity of 14% vs. 11%. 3-year-BFS was
significantly higher in the hypofractionated arm (87% vs.
79%, p=0,035). In line with these data, investigators of
a randomised phase III trial [14] comparing 55 Gy in
2.75 Gy single doses with 64 Gy in 2 Gy single doses
saw no difference in late gastrointestinal (GI) and GU
toxicity, while the BFS rate at 90 months was statisti-
cally significantly higher in the hypofractionated group
(53% vs. 34%).
While hypofractionated regimen are beginning to be
integrated into clinical routine in first line treatment,
data on postoperative hypofractionated radiotherapy is
still sparse. Kruser et al. observed low toxicity rates in
108 patients treated with 65 Gy in 2.5 Gy single dose:
Only one patients suffered from acute grade 3 GU tox-
icity and no acute grade 3 GI toxicities occurred. No
patient suffered from any late grade 3 toxicity [15].While the early trials on prostate radiotherapy have
been conducted with conventional radiation techniques,
it has been demonstrated that the dose to the prostate
can be escalated with intensity-modulated radiotherapy
(IMRT) without the risk of higher toxicity [16,17]. In
addition, sophisticated imaging devices have been imple-
mented in daily routine that can ensure exact dose appli-
cation. Helical Tomotherapy (HT) constitutes a fusion
of a linear accelerator with a spiral CT scanner, offering
the possibility of MV-CT imaging with good soft tissue
contrast before each treatment fraction combined with
IMRT treatment with sharp dose gradients [18,19].
We initiated this phase II trial to investigate the tox-
icity profile and efficacy of a hypofractionated postopera-
tive radiotherapy of the prostate bed with or without the
inclusion of the pelvic lymph nodes using HT under
daily image guidance.Methods/design
Study design
The PRIAMOS trial is a single-center, non-randomised
prospective two-arm prospective phase II trial. Patients
will be stratified according to their risk of lymphatic in-
volvement into either hypofractionated radiotherapy of
the prostate bed alone with 54 Gy in 18 fractions of
3.0 Gy each (low risk of lymph node involvement, arm 1,
PRIAMOS 1) or additional simultaneous treatment of
the pelvic lymph nodes with 45 Gy in 18 fractions of
2.5 Gy (high risk of lymph node involvement, arm 2,
PRIAMOS 2). Patients eligible for the PRIAMOS trial
have to present with the indication for a radiotherapy of
the prostate bed. Patients with a risk of lymph node in-
volvement of >20% according to the Roach formula [20]
(2/3 PSA + [Gleason - 6] x 10) with inadequate lympha-
denectomy (< 10 lymph nodes) and patients with posi-
tive resected nodes (pN1) are attributed to arm 2 and
receive a simultaneous treatment of the pelvic lymph
nodes. For the trial flowchart, see Figure 1.Study objectives
The main objective is to demonstrate the safety and fea-
sibilty of a hypofractionated helical IMRT of the prostate
bed with (PRIAMOS 2) or without (PRIAMOS 1) the
pelvic lymph nodes. Treatment safety will be judged by
the incidence of NCI CTC AE grade 3–4 toxicity and by
occurrence of treatment discontinuation.
Secondary objectives are BFS, quality of life (QoL) and
clinical symptoms. A biochemical recurrence is defined
as 3 consecutive rises in PSA levels (ASTRO criteria).
QoL is investigated using the EORTC QLQ-C30 and
QLQ-PR25 questionnaires; symptoms and toxicities will
be graded using the NCI CTC AE version 4.0 grading
criteria.
Resected prostate carcinoma with indication 
for a radiotherapy of the prostate bed without
macroscopic lymph node metastases in situ
and without distant metastases
Risk of lymph node involvement  20% 
or pN0 with adequate lymphonodectomy
Risk of lymph node involvement >20% 
or pN1 and inadequate 
lymphonodectomy (<10)
neoadjuvant hormonal suppression and 




(18x 3 Gy to prostate bed)
PRIAMOS 2
(18x3 Gy to prostate bed +
18x2.5 Gy to pelvic lymph nodes)
Figure 1 Trial flowchart.
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The PRIAMOS trial is a single-center, investigator-
initiated trial carried out by the Department of Radiation
Oncology, University Hospital of Heidelberg, Germany.
Patient selection: inclusion criteria
Patients meeting all of the following criteria are eligible
for the PRIAMOS trial:
 resected prostate carcinoma with histological
grading (Gleason Score)
 status post prostatectomy for a pT3 carcinoma
and/or R1/2 resection or PSA recurrence after
prostatectomy (2 consecutive PSA rises)
 PSA recurrence ≥ 1 ng/ml: CT/PET/MRI imaging
excluding pathological lymph nodes
 Karnofksy performance score ≥ 70%
 age 18–80 years
 only arm 2: antihormonal therapy for 2 months
prior to radiotherapy and continuation of
hormonal suppression after radiotherapy
recommended
 written informed consent
Patient selection: exclusion criteria
Patients meeting at least one of the following criteria are
not eligible for the PRIAMOS trial:
 patient‘s refusal
 patient‘s inabillity to give informed consent
 stage IV (distant metastases)
 lymph node involvement outside the pelvis
 severe wound complications after laparatomy
 only arm 2: severe lymphoedema of the legs,
elephantiasis, postthrombotic syndrome decompensated pulmonary, cardiovascular,
metabolic, hematopoetic, coagulatory or renal
comorbidities
 known other malignant disease with distant
metastases
 prior pelvic irradiation
 participation in another clinical trial that might
compromise the results of the PRIAMOS trial or the
other trial
Statistical design
Each of the two arms (PRIAMOS 1 and PRIAMOS 2) is
designed an independent single stage phase II trial with
the safety and feasibility the respective treatment as pri-
mary endpoint, precisely defined as the proportion SDR
of patients with no NCI CTC AE grade 3–4 toxicity and
no discontinuation of treatment during the full set of 18
fractions by any reasons in the intent-to-treat (ITT)
population. The ITT population is defined by compliance
with the in- and exclusion criteria and not dropping out
within one week after start of treatment.
The study hypothesis is chosen as H1: SDR≥ 95% to
be tested versus the null hypothesis of H0: SDR≤ 80%
using a single arm exact binomial test for proportions.
In order to test H0 versus H1 one-sided at the signifi-
cance level of 0.10 (10%) n= 32 evaluable patients are
required to achieve a power of 90%, when using PASS
software and A’Hern [21] and choosing the type I and
the type II error identical for such a phase II trial. In
order to compensate possible drop out between
informed consent and treatment for at least one week
n=40 patients are planned to be recruited per arm.
No formal interim analysis is scheduled. However, re-
cruitment is put on hold in an arm when the proportion
SDR surpasses the critical number of 4. The study
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ment of the respective as well as the other trial arm.
Statistical evaluation of the primary endpoint as well
as of the secondary endpoints BFS, QoL, overall survival
and detailed safety analysis will be performed separately
for each arm, for the ITT (SDR, BFS, QoL) as well as for
the per protocol (PP; SDR,BFS) and the safety (SF; QoL,
NCI CTC AE) population. Statistical comparisons be-




For each patient, the decision to treat the prostate bed is
made by a radiation oncologist based on the S3-guideline
of the German Society of Urology [1]. Indications for a
postoperative or salvage radiotherapy of the prostate bed
are a stage pT3, microscopically or macroscopically posi-
tive resection margins (R1/2) or a PSA recurrence after
prostatectomy. For patients with a risk of lymph node in-
volvement according to the Roach formula (2/3 PSA +
[Gleason - 6] x 10) > 20% and inadequate (<10) lymphade-
nectomy, the additional simultaneous treatment of the
pelvic lymph nodes is indicated.
Pre-Therapeutic examinations
Prior to treatment, a complete medical history including
the surgical report and the histological examination is
taken. In the case of a PSA ≥ 1 ng/ml, a recent CT, MRI
or PET ruling out pathological lymph nodes, and in the
case of a PSA ≥ 3 ng/ml a bone scintigraphy ruling out
bone metastases have to be performed before the start of
an antihormonal treatment. A baseline QoL assessment
as well baseline symptoms are recored prior to start of
treatment. At the first treatment day, PSA levels and
haemogram are measured.
Planning of radiotherapy
Before start of radiotherapy, a planning CT in 3 mm
slices is taken without contrast medium. The patient is
positioned using a knee and foot support. During plan-
ning CT scan and when treatment fractions adminis-
tered, the bladder should be full and the rectum empty.
The PTV-P (planning target volume-prostate bed) com-
prises the prostate bed including the bottom of the blad-
der and the anterior rectal wall with a security margin of
0.5 cm. For arm 2, an additional PTV-L (planning target
volume-lymph nodes) including the obturatory, perirectal,
internal and external iliac, common iliac and presacral
lymph nodes according to the RTOG guidelines [22] with
a 0.5 cm margin is contoured. Intersections of PTV-P with
the rectum and of PTV-L with the small bowel are con-
structed to avoid hotspots in rectum and small bowels.
Rectum, bladder, small bowel and femoral heads arecontoured as organs at risk. A dose of 54 Gy in 3 Gy daily
fractions is prescribed to 95% of the PTV-P. Additionally,
in arm 2, a dose of 45 Gy in 2.5 Gy fractions is prescribed
to 95% of the PTV-L. Assuming an α/β of 1.5 Gy for pros-
tate cancer, this translates to an equivalent dose of
69.4 Gy to the prostate bed and 51.4 Gy to the lymph
nodes. As planning constraints, a maximum dose to the
small bowels of 45 Gy, even if resulting in a reduced
coverage of PTV-L, has to be respected. Dose to all organs
at risk should be kept as low as possible, and the TD 5/5
of the respective organs must not be exceeded.
Radiation therapy
Radiotherapy is performed as a helical IMRT using a
TomotherapyW Hi-Art or HD unit (Accuray Inc., Sunnyvale,
CA, USA). Before each treatment, a 3.5 MV fan beam
CT is performed and matched to the planning CT. If
needed, the patient positioning is corrected. If neces-
sary, rectal and bladder filling are adjusted before the
start of treatment. Treatment is performed in 18 daily
fractions (Monday-Friday only). Radiotherapy is con-
ducted on an outpatient basis with the possibilty of
hospitalisation if required.
Monitoring during treatment
During treatment, constant clincal monitoring and, if
necessary, supportive therapy, is guaranteed. Once
weekly, symptoms and toxicities are assessed and the
haemogram is measured. PSA is not measured during
treatment. The following symptoms and toxicities are of
special clinical interest: urinary incontinence, nocturia,
cystitis, stool frequency, stool incontinence, diarrhoea,
proctitis, lymphoedema and virility.
Follow-up
A first PSA measure after treatment is taken 6 weeks after
the end of radiotherapy and then every three months.
Toxicity and symptoms are recorded at 6 weeks, 6 months,
12 months, 18 months and 24 months after radiotherapy.
QoL is assessed at 6 weeks, 6 months and 24 months after
radiotherapy using the EORTC questionnaires.
Duration of the study
Patient accrual started in March 2012; the end of accrual
is planned for March 2014. Analysis of the primary end-
point for each separate arm is planned for 24 months
after the first treatment day of the last patient, and the
end of the study is defined as the end of the last patient‘s
observation period.
Data handling, storage and archiving of data
All clinical and laboratory data and radiotherapy plans
will be documented by the investigators or an authorised
member of the study team in the patient‘s medical record
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stored and archived according to §13 of the German
GCP Regulation and §28c of the German X-Ray Regula-
tion (StrSchV) for at least 30 years after the trial
termination.
Ethics, informed consent and safety
The final trial protocol was approved by the ethics commit-
tee of the Medical Faculty of the University of Heidelberg,
Germany (Nr.: S-599/2011). An expert committee of the
German Society of Radiation Oncology (DEGRO) approved
the protocol and stated that the trial did not need a vote of
the Federal Office for Radiation Protection (Bundesamt für
Strahlenschutz, BfS). The study complies with the Helsinki
Declaration in its recent German version. The trial is also
carried out in keeping with local legal and regulatory
requirements.
Discussion
In definitive radiotherapy for prostate cancer, hypofrac-
tionation is being integrated into standard treatment
regimen in an increasing amount of treatment centers.
Similar toxicity rates and at least equal efficacy have been
affirmed by several non-randomised and randomised
trials [12,14,23]. Moreover, several large randomised
phase III trials are recruiting currently or have just fin-
ished recruiting: A trial of the Fox Case Cancer Center
compares 76 Gy in 2 Gy fractions vs. 70.2 Gy in 2.7 Gy
fractions, while a NCIC trial randomises patients to
78 Gy in 2 Gy fractions or 60 Gy in 3 Gy fractions.
RTOG 0415 randomises low-risk patients to 73.8 Gy in
1.8 Gy fractions or 70 Gy in 2.5 Gy fractions. Should the
α/β for prostate cancer be 10 Gy, both arms would be
isoeffective. With an α/β of 1.5 Gy, however, the biologic-
ally effective dose (BED) would be 15% higher in the
hypofractionated arm and should result in a better clin-
ical outcome.
While hypofractionated radiotherapy in the definitive
setting has been investigated extensively, data on post-
operative hypofractionated treatment is sparse. An
Italian phase I-II trial [24] treated 50 patients with
helical IMRT using 58 Gy in 2.8 Gy fractions with
excellent safety outcomes that were comparable to
their data on conventionally fractionated treatment.
Twelve percent of their patients suffered from acute
grade 2–3 GU side effects and 4% from acute grade 2
intestinal side effects. No acute grade 2 proctitis and
no late grade 2 GI sequelae were reported. Similarly
low toxicity rates have been demonstrated by Kruser
and colleagues by treating the prostate bed with
65 Gy in 2.5 Gy fractions [15]. To our knowledge,
there is no clinical data on a hypofractionated treat-
ment of the pelvic lymph nodes. However, dose-
escalated treatment of the pelvic nodes with 56 Gy inconventional fractionation combined with hypofractio-
nated treatment of the prostate (70 Gy in 2.5 Gy frac-
tions) has been shown to be well tolerated [25].
We chose a fractionation regimen with 54 Gy in 3 Gy
fractions to the prostate bed with or without the treat-
ment of the pelvic lymph nodes with 45 Gy in 2.5 Gy
fractions. Assuming an α/β of 1.5 Gy, the BED is
69.4 Gy for the prostate bed and 51.4 Gy for the pelvic
lymph nodes. These prescriptions are well below the tol-
erance doses of the respective organs at risk such as
small bowel (BED 47.5 Gy, α/β 7 Gy) and rectum (BED
63 Gy, α/β 4 Gy). If, contrary to recent clinical data, the
α/β for prostate cancer is as high as 10 Gy, our prescrip-
tion would result in a BED of 58.5 Gy to the prostate
bed and 46.9 Gy to the lymphatic drainage.
This phase II trial was initiated to substantiate the data
on safety and efficacy of postoperative hypofractionated
irradiation of the prostate bed, to investigate for the first
time hypofractionated treatment of the pelvic lymph
nodes and to compare toxicity rates of hypofractionated
treatment of the prostate bed alone or with the lymph-
atic drainage. A safe and effective hypofractionated regi-
men is attractive for radiation oncology facilities and for
patients: While treatment facilities benefit from a higher
throughput, patient comfort is increased by a shorter
treatment duration.
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